Avenue Therapeutics Inc <ATXI.OQ> expected to post a loss of 57 cents a share - Earnings Preview

• Avenue Therapeutics Inc ATXI.OQ ATXI.O is expected to show no change in quarterly revenue when it reports results on March 17 (estimated) for the period ending December 31 2024

• ​LSEG's mean analyst estimate for Avenue Therapeutics Inc is for a loss of 57 cents per share.

• The one available analyst rating on the shares is "buy".

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Avenue Therapeutics Inc is $8.00​, above​ its last closing price of $0.77. ​​​

This summary was machine generated March 14 at 20:14 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)